This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Inhalation (NCT04631705), a randomized phase 1, phase 2 study. The primary outcome is Proportion of Patients With Any AE Within 7 d of Study Drug Administration.
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT04631705 |
| Phase | Phase 1, Phase 2 |
| Condition | SARS-CoV-2 Infection |
| Allocation | Randomized |
| Design model | Sequential |
| Masking | Triple |
| Enrollment | 45 |
| Arms in the primary outcome | 9 |
| Lead sponsor | University of Cologne |
| Results posted | Yes |
2. Clinical Question
Population
The trial enrolled healthy, SARS-CoV-2-uninfected volunteers and SARS-CoV-2-infected volunteers. The registry lists an enrollment of 45. It describes the study as the first-in-human trial of inhaled DZIF-10c. The posted results separate participants into healthy and infected dose groups, with an additional randomized group of infected participants.
Intervention
The intervention was DZIF-10c, a SARS-CoV-2-neutralizing monoclonal antibody, given by inhalation at listed doses of 50 mg, 100 mg, or 250 mg. In the additional infected group, participants were assigned to inhaled DZIF-10c with intravenous DZIF-10c, inhaled DZIF-10c with intravenous placebo, or placebo by both routes.
Comparator
Placebo was used in the infected group receiving placebo by inhalation and infusion. The registry describes randomization in that group as 1:1:1 across its three treatment combinations. The posted primary outcome also includes healthy and infected dose groups without a placebo comparator, so those groups are not all part of a single direct comparison.
Primary question
The primary endpoint counts participants with any adverse event during the first 7 days after study drug administration. It is a short-term safety measure, not a measure of antiviral activity. The registry lists counts for each arm, but it does not report an analysis comparing treatments or an estimate of a treatment effect.
3. Trial Design
This was a randomized phase 1/2a study of inhaled DZIF-10c in SARS-CoV-2-infected and uninfected individuals. The registry describes masking as triple and the study model as sequential. The sponsor was the University of Cologne. The study started on 2020-12-14, and the listed primary completion date is 2021-09-23. Its status is terminated; the reason for termination is not reported in the registry record.
The registry describes dose groups in both healthy and infected volunteers. The listed inhaled doses were 50 mg, 100 mg, and 250 mg. In the additional infected group, participants were randomized 1:1:1 to inhaled DZIF-10c plus intravenous DZIF-10c, inhaled DZIF-10c plus intravenous placebo, or placebo by both inhalation and infusion. The record does not specify the details of how the sequential design operated, how dose groups were entered, or how masking was maintained across the different routes and groups.
The primary outcome was the number of participants with any adverse event during the first 7 days after study drug administration. Posted group sizes ranged from 3 to 10 participants. The registry reports 45 enrolled participants overall. The listed group counts and outcome counts describe the posted results; the record does not explain whether every enrolled participant contributed to every outcome or how any exclusions were handled.
The registry also names secondary outcomes concerning DZIF-10c area under the curve, anti-drug antibody development, and viral-load change from baseline using time-weighted and MMRM approaches. Numerical findings for those outcomes are not reported in the registry record. No detailed statistical analysis plan, sample-size justification, interim-analysis plan, or explanation of the termination is reported in the registry record.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Only the first 6 of 9 groups are shown.
Overall Study
| Stage | 1A: Healthy, 50 mg Inh. | 1B: Healthy, 100 mg Inh. | 1C: Healthy, 250 mg Inh. | 2A: Infected, 50 mg Inh. | 2B: Infected, 100 mg Inh. | 2C: Infected, 250 mg Inh. |
|---|---|---|---|---|---|---|
| STARTED | 3 | 3 | 3 | 3 | 3 | 3 |
| COMPLETED | 3 | 3 | 3 | 3 | 3 | 3 |
| NOT COMPLETED | 0 | 0 | 0 | 0 | 0 | 0 |
Reasons for not completing this period:
| Reason | 1A: Healthy, 50 mg Inh. | 1B: Healthy, 100 mg Inh. | 1C: Healthy, 250 mg Inh. | 2A: Infected, 50 mg Inh. | 2B: Infected, 100 mg Inh. | 2C: Infected, 250 mg Inh. |
|---|---|---|---|---|---|---|
| Withdrawal by Subject | 0 | 0 | 0 | 0 | 0 | 0 |
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
Only the first 6 of 10 groups are shown.
| Characteristic | Unit | 1A: Healthy, 50 mg Inh. | 1B: Healthy, 100 mg Inh. | 1C: Healthy, 250 mg Inh. | 2A: Infected, 50 mg Inh. | 2B: Infected, 100 mg Inh. | 2C: Infected, 250 mg Inh. |
|---|---|---|---|---|---|---|---|
| Participants analysed | 3 | 3 | 3 | 3 | 3 | 3 | |
| Age, Continuous | years | 43 (29 to 44) | 33 (32 to 44) | 27 (20 to 29) | 35 (30 to 62) | 39 (25 to 42) | 41 (32 to 46) |
| Sex: Female, Male: Female | Participants | 0 | 1 | 2 | 1 | 2 | 1 |
| Sex: Female, Male: Male | Participants | 3 | 2 | 1 | 2 | 1 | 2 |
| Race and Ethnicity Not Collected | Participants | — | — | — | — | — | — |
| Region of Enrollment: Germany | participants | 3 | 3 | 3 | 3 | 3 | 3 |
6. Primary Endpoint
The registry lists the primary outcome as Proportion of Patients With Any AE Within 7 d of Study Drug Administration, measured over Over first 7 days after study drug administration.
| Element | Registry entry |
|---|---|
| Result type | Count Of Participants |
| Measure of spread | not applicable |
| Unit | Participants |
| Endpoint classification | Binary Endpoint |
The primary endpoint is the count of participants who experienced any adverse event over the first 7 days after study drug administration. It is reported as participants, rather than as a continuous measurement or a time-to-event quantity. The endpoint therefore describes whether a participant had at least one event in the stated period; it does not communicate how many events an affected participant experienced, how long an event lasted, or its severity.
General statistical context: early-phase trials commonly monitor safety and tolerability while a treatment is being studied in people. Counting participants with any adverse event offers a straightforward way to describe the share of each group with at least one event, although the posted results give counts and group sizes rather than a formal comparative estimate. The endpoint is not itself a measure of antiviral activity, pharmacokinetics, or antibody development, despite those being among the trial’s broader aims.
The observed counts differ across the listed groups, but the groups include healthy and infected participants, different doses, and different treatment combinations. A count alone does not show whether an event was caused by study treatment. The registry does not report endpoint definitions beyond any adverse event, nor does it give event-level descriptions for this primary outcome. A formal between-group analysis is not reported in the registry record.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The posted primary outcome is a set of participant counts within the first 7 days after study drug administration. In the healthy groups, the registry records 2 of 3 participants in the 50 mg inhaled group, 1 of 3 in the 100 mg group, and 1 of 3 in the 250 mg group as having any adverse event. Among the infected dose groups, the corresponding counts are 3 of 3, 1 of 3, and 0 of 3. In the additional infected group, the counts are 6 of 10 with placebo by both routes, 3 of 8 with 250 mg inhaled DZIF-10c and intravenous placebo, and 3 of 9 with 250 mg inhaled plus 40 mg/kg intravenous DZIF-10c.
These are descriptive results from small groups. In groups with only 3 participants, a change in the status of one participant would materially alter the count. The counts do not establish that differences between groups are due to treatment. Interpretation is further limited because the groups do not all represent the same population or treatment contrast: some include healthy volunteers, some include infected volunteers, and the infected treatment group includes distinct route combinations.
The registry lists no statistical analyses for the outcomes. It does not report a risk difference, risk ratio, confidence interval, p-value, or adjusted estimate for the primary endpoint. Values for a two-arm binary comparison are missing or not estimable in the posted results. Accordingly, the available information supports description of the reported counts, not a claim of a statistically demonstrated difference between treatment groups.
The adverse-event counts should also be distinguished from the separately listed serious adverse event figures. The registry reports zero participants with serious adverse events and zero deaths in each listed group. These are separate safety summaries and should not be treated as a substitute for the primary any-adverse-event outcome. The reason that the primary outcome counts do not match every count in the adverse-event summary is not explained in the registry record.
The study’s terminated status is an important part of the record but does not explain why the trial ended or whether termination changed the planned analyses. The registry lists four secondary outcome topics but does not report their numerical findings. The record therefore gives only a limited view of the study’s intended assessment of pharmacokinetics, immunogenicity, and antiviral activity. No efficacy conclusion follows from the primary safety counts.
9. Statistical Methods Explained
What does a participant count communicate?
For this binary outcome, a participant either met the endpoint definition during the stated period or did not. The registry presents the number meeting the endpoint alongside the number in each group. General statistical context: this form of reporting makes the observed event experience visible without implying that each event was equally severe or that all affected participants had the same experience. A count is not a treatment-effect estimate. To compare groups, an analysis would normally define a contrast and quantify uncertainty around that contrast.
The primary endpoint is limited to any adverse event within the first 7 days after study drug administration. It does not describe events outside that period, repeated events in one participant, or event severity. The registry record does not report more detailed endpoint criteria, such as how events were classified or whether assessment differed across participant groups. Those details matter because a broad endpoint can combine events with different clinical meanings.
Why are group comparisons difficult?
The listed arms are not interchangeable samples from one common population. They include uninfected and infected volunteers, different inhaled doses, and combinations of inhaled and intravenous treatment or placebo. A direct comparison is most interpretable when groups differ only in the treatment feature under study and are otherwise comparable. Randomization is listed for the trial, and the record specifically describes 1:1:1 randomization in the additional infected group, but it does not supply an analysis that estimates a treatment contrast.
Group sizes are small, ranging from 3 to 10 participants. General statistical context: with few participants, each observed outcome has substantial influence on the group’s count, and uncertainty around a comparison is generally wide. Small groups also offer limited ability to detect uncommon outcomes. The registry does not report confidence intervals or other uncertainty measures for the primary endpoint, so its precision cannot be assessed from an inferential estimate.
What do significance tests and confidence intervals add?
General statistical context: a confidence interval describes a range of values compatible with the data under a specified statistical model and procedure. It helps convey uncertainty in an estimate; it does not guarantee that the true value lies in the interval. A significance test addresses compatibility of data with a specified null hypothesis under its assumptions. Neither type of result is reported for the primary outcome in the registry record. There is therefore no posted p-value or interval with which to assess statistical evidence or precision.
The registry records zero analyses. It also indicates that values for a two-arm binary comparison are missing or not estimable. This means the numerical arm counts should not be mistaken for a completed sponsor-reported comparative analysis. No recalculated comparison is presented in the posted results, and no sponsor analysis is available to take precedence over an unadjusted re-calculation.
How should planning illustrations be understood?
General statistical context: sample-size calculations describe the number of participants that a hypothetical design might require under stated assumptions. They are planning illustrations, not observed power and not evidence that a completed trial had a particular chance of detecting an effect. The registry’s stated illustration assumptions use a two-sided significance level of 0.05, equal allocation between two arms, a normal approximation, and an effect expressed as a fraction of the observed effect. For time-to-event outcomes, its stated convention concerns total events; for other outcomes, it concerns participants per arm.
The available record does not provide a numerical comparative effect for this binary endpoint, and the two-arm comparison is listed as missing or not estimable. No numerical planning results or fractions are reported in the registry record. Consequently, the assumptions alone cannot establish a sample-size justification for this trial. The registry does not report the trial’s own sample-size rationale or whether a target was revised during conduct.
What can be concluded from the methods information?
The registry identifies a randomized, triple-masked, sequential phase 1/2a trial and reports the primary outcome and arm-level counts. It does not report the full statistical plan, prespecified contrasts, method for handling missing outcome data, adjustment strategy, or analysis population definitions. Those omissions preclude a detailed appraisal of how the reported numbers relate to a prespecified analysis. The available statistics should therefore be read as descriptive registry results with limited comparative interpretation.
10. Exact Estimates for Each Arm
No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.
| Arm | Participants | Events | Observed % | Clopper-Pearson 95% CI | Wilson 95% CI | Bayesian 95% credible interval |
|---|---|---|---|---|---|---|
| 1A: Healthy, 50 mg Inh. | 3 | 2 | 66.7% | 9.4% to 99.2% | 20.8% to 93.9% | 19.4% to 93.2% |
| 1B: Healthy, 100 mg Inh. | 3 | 1 | 33.3% | 0.8% to 90.6% | 6.1% to 79.2% | 6.8% to 80.6% |
| 1C: Healthy, 250 mg Inh. | 3 | 1 | 33.3% | 0.8% to 90.6% | 6.1% to 79.2% | 6.8% to 80.6% |
| 2A: Infected, 50 mg Inh. | 3 | 3 | 100.0% | 29.2% to 100.0% | 43.9% to 100.0% | 39.8% to 99.4% |
| 2B: Infected, 100 mg Inh. | 3 | 1 | 33.3% | 0.8% to 90.6% | 6.1% to 79.2% | 6.8% to 80.6% |
| 2C: Infected, 250 mg Inh. | 3 | 0 | 0.0% | 0.0% to 70.8% | 0.0% to 56.1% | 0.6% to 60.2% |
R code and output
arm <- c("1A: Healthy, 50 mg Inh.", "1B: Healthy, 100 mg Inh.", "1C: Healthy, 250 mg Inh.", "2A: Infected, 50 mg Inh.", "2B: Infected, 100 mg Inh.", "2C: Infected, 250 mg Inh.")
n <- c(3, 3, 3, 3, 3, 3)
events <- c(2, 1, 1, 3, 1, 0)
for (i in seq_along(n)) {
ci <- binom.test(events[i], n[i])$conf.int # Clopper-Pearson exact interval
cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i]) # Bayesian, uniform Beta(1,1) prior
wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}
ARM 1A: Healthy, 50 mg Inh. 3 2 66.7 9.4 99.2 20.8 93.9 19.4 93.2
ARM 1B: Healthy, 100 mg Inh. 3 1 33.3 0.8 90.6 6.1 79.2 6.8 80.6
ARM 1C: Healthy, 250 mg Inh. 3 1 33.3 0.8 90.6 6.1 79.2 6.8 80.6
ARM 2A: Infected, 50 mg Inh. 3 3 100.0 29.2 100.0 43.9 100.0 39.8 99.4
ARM 2B: Infected, 100 mg Inh. 3 1 33.3 0.8 90.6 6.1 79.2 6.8 80.6
ARM 2C: Infected, 250 mg Inh. 3 0 0.0 0.0 70.8 0.0 56.1 0.6 60.211. Multiplicity, Missing Data and Analysis Populations
The registry names four secondary outcomes: DZIF-10c area under the curve, anti-drug antibody development, time-weighted SARS-CoV-2 viral-load change from baseline, and MMRM SARS-CoV-2 viral-load change from baseline. It lists four posted secondary outcomes, but numerical findings for them are not reported in the registry record. The record does not describe which outcomes were designated for formal hypothesis testing, how multiple comparisons were to be handled, or whether any hierarchy of outcomes was prespecified. Without that information, the multiplicity implications of testing several outcomes cannot be assessed.
Missing-data methods are not reported in the registry record. The record does not describe how participants with incomplete follow-up, missing measurements, or unavailable endpoint assessments were handled. It also does not state whether the primary analysis used all randomized participants, participants who received treatment, or another analysis population. Although the registry lists an enrollment of 45 and arm-level denominators, those details alone do not establish the analysis-population rules or account for missing observations.
No interim-analysis plan, stopping boundary, or adjustment for interim monitoring is reported in the registry record. The trial is marked terminated, but the reason and any implications for planned analyses are not reported. These gaps mean that the posted counts can be described, while the effects of missing data, outcome selection, or repeated statistical testing cannot be evaluated from the registry information.
12. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| 1A: Healthy, 50 mg Inh. | 0 | 3 | 0.0% |
| 1B: Healthy, 100 mg Inh. | 0 | 3 | 0.0% |
| 1C: Healthy, 250 mg Inh. | 0 | 3 | 0.0% |
| 2A: Infected, 50 mg Inh. | 0 | 3 | 0.0% |
| 2B: Infected, 100 mg Inh. | 0 | 3 | 0.0% |
| 2C: Infected, 250 mg Inh. | 0 | 3 | 0.0% |
| 2D: Infected, Placebo Inh., Placebo i.v. | 0 | 10 | 0.0% |
| 2D: Infected, 250 mg Inh., Placebo i.v. | 0 | 8 | 0.0% |
| 2D: Infected, 250 mg Inh., 40 mg/kg i.v. | 0 | 9 | 0.0% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| 1A: Healthy, 50 mg Inh. | 0 of 3 |
| 1B: Healthy, 100 mg Inh. | 0 of 3 |
| 1C: Healthy, 250 mg Inh. | 0 of 3 |
| 2A: Infected, 50 mg Inh. | 0 of 3 |
| 2B: Infected, 100 mg Inh. | 0 of 3 |
| 2C: Infected, 250 mg Inh. | 0 of 3 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 0% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| 1A: Healthy, 50 mg Inh. | 2 of 3 |
| 1B: Healthy, 100 mg Inh. | 1 of 3 |
| 1C: Healthy, 250 mg Inh. | 2 of 3 |
| 2A: Infected, 50 mg Inh. | 3 of 3 |
| 2B: Infected, 100 mg Inh. | 2 of 3 |
| 2C: Infected, 250 mg Inh. | 2 of 3 |
Most frequent non-serious adverse event terms
| Event term | Organ system | 1A: Healthy, 50 mg Inh. | 1B: Healthy, 100 mg Inh. | 1C: Healthy, 250 mg Inh. | 2A: Infected, 50 mg Inh. | 2B: Infected, 100 mg Inh. | 2C: Infected, 250 mg Inh. |
|---|---|---|---|---|---|---|---|
| Headache | Nervous system disorders | 1 of 3 | 0 of 3 | 0 of 3 | 2 of 3 | 0 of 3 | 1 of 3 |
| Thrombocytopenia | Blood and lymphatic system disorders | 0 of 3 | 0 of 3 | 0 of 3 | 2 of 3 | 0 of 3 | 0 of 3 |
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | 0 of 3 | 0 of 3 | 0 of 3 | 2 of 3 | 0 of 3 | 0 of 3 |
| Cough | Respiratory, thoracic and mediastinal disorders | 0 of 3 | 1 of 3 | 1 of 3 | 0 of 3 | 0 of 3 | 0 of 3 |
| Inflammation | General disorders | 1 of 3 | 0 of 3 | 0 of 3 | 0 of 3 | 0 of 3 | 0 of 3 |
| Pyrexia | General disorders | 0 of 3 | 0 of 3 | 0 of 3 | 0 of 3 | 1 of 3 | 0 of 3 |
| Alanine aminotransferase increased | Investigations | 0 of 3 | 0 of 3 | 0 of 3 | 0 of 3 | 0 of 3 | 1 of 3 |
| Lipase increased | Investigations | 0 of 3 | 0 of 3 | 0 of 3 | 1 of 3 | 0 of 3 | 0 of 3 |
| Ventricular arrhythmia | Cardiac disorders | 1 of 3 | 0 of 3 | 0 of 3 | 0 of 3 | 0 of 3 | 0 of 3 |
| Leukopenia | Blood and lymphatic system disorders | 0 of 3 | 0 of 3 | 0 of 3 | 1 of 3 | 0 of 3 | 0 of 3 |
The serious adverse event summary reports zero affected participants in every listed group, and the death count is zero in every listed group. These are counts, not comparative estimates. The group sizes were small, ranging from 3 to 10 participants, so the absence of a recorded serious event in these groups does not establish that serious events could not occur or provide a precise estimate of their frequency.
The primary endpoint is broader: it counts participants with any adverse event during the first 7 days after study drug administration. The serious-event summary is distinct from that endpoint. The registry also lists other adverse event counts, but the record does not explain the relationship between those counts and the primary outcome in every arm. For example, the listed primary outcome count for the infected 250 mg inhaled group is 0 of 3, while the other-adverse-event summary lists 2 affected participants in that group. The registry does not explain this difference, so the figures should not be combined or treated as equivalent measures.
General statistical context: serious adverse events and all adverse events answer different descriptive questions. The former focuses on events classified as serious; the latter is broader. The registry does not provide event terms for serious adverse events, and the list of top serious terms is empty. These safety summaries describe what was recorded, not whether a treatment caused an event.
13. What the Result Does, and Does Not, Mean
The results show the numbers of participants recorded as having any adverse event during the first 7 days after study drug administration in each listed group. They also show zero participants with serious adverse events and zero deaths in the posted safety summary. The primary counts are descriptive and come from small groups that differ in infection status, dose, and treatment route. They provide a record of observed events, but do not on their own establish differences between treatments.
The registry does not report a comparative statistical analysis, confidence intervals, or p-values for the primary outcome. It therefore does not quantify the uncertainty around a treatment contrast or demonstrate that any observed count difference reflects a treatment effect. Nor do zero serious adverse events or deaths in these groups establish the absence of risk. The small group sizes and lack of detailed event-level information limit what can be concluded about uncommon or specific harms.
The broader study aimed to evaluate safety, pharmacokinetics, immunogenicity, and antiviral activity. The listed secondary outcomes concern drug exposure, anti-drug antibodies, and viral-load changes, but their numerical findings are not reported in the registry record. The primary safety outcome cannot substitute for those outcomes and does not provide evidence about antiviral activity.
The trial’s terminated status is recorded, but the reason is not reported in the registry record. Without that context, it is not possible to infer whether termination was related to safety, feasibility, recruitment, or another consideration. The most defensible reading is therefore narrow: the record documents short-term adverse-event counts and no reported serious adverse events or deaths in the listed groups, while leaving comparative effects and the broader study aims unresolved.
14. Why This Trial Matters Statistically
This trial illustrates the statistical challenges of interpreting early-phase studies with several small groups. Its design included uninfected and infected volunteers, multiple inhaled doses, and a randomized infected group with different inhaled and intravenous treatment combinations. These features allow the record to describe several treatment settings, but they also mean that one should not treat every arm as a direct comparator for every other arm.
The primary outcome is a simple participant-level count, which is accessible and relevant to short-term safety description. But such a count has limited precision in groups of 3 to 10 participants. General statistical context: small samples make estimates sensitive to individual observations and constrain conclusions about uncommon events. A formal estimate with uncertainty would help readers distinguish the observed group counts from the range of effects compatible with the data; such estimates are not reported in the registry record.
The record also demonstrates why a registered outcome list and an analysis report are not the same thing. The registry names secondary outcomes relevant to drug exposure, immunogenicity, and viral load, but does not report numerical results for them. It lists no analyses and does not describe multiplicity handling, missing-data methods, or analysis populations. These omissions make it difficult to connect the stated objectives to completed statistical evidence.
Finally, the terminated status calls for attention to study context without inviting speculation. The reason for termination and any impact on the planned statistical work are not reported. The trial is therefore informative as a record of its design and posted safety counts, while its comparative and broader scientific conclusions remain limited by the analyses and outcome results available in the registry.
15. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The posted results do not include a comparative analysis of the primary binary endpoint. The registry lists no analyses and indicates that two-arm comparison values are missing or not estimable. No confidence intervals, p-values, adjusted estimates, or prespecified contrast results are reported. As a result, interpretation is limited to the counts and group sizes rather than an estimate of how treatments compare.
Group sizes are small, and the arms differ in infection status, dose, and route of administration. The registry does not report the detailed allocation procedures for all groups or explain how the sequential model was implemented. It also does not give enough information to determine whether all groups were assessed under identical endpoint procedures. The definition of any adverse event is stated broadly, without additional event-classification details for the primary outcome.
The adverse-event summary and primary outcome counts are not fully aligned in at least one listed group, and the registry does not explain the discrepancy. The record also does not report event-level terms for the primary endpoint. Numerical results for the secondary outcomes are not reported in the registry record, limiting assessment of pharmacokinetic, immunogenicity, and antiviral objectives.
Missing-data handling, analysis populations, multiplicity procedures, sample-size justification, interim analyses, and the reason for termination are not reported in the registry record. The reported absence of serious adverse events and deaths should be interpreted in light of the small groups and cannot establish that such events are impossible or provide a precise risk estimate.
16. Related Tutorials
17. Related Statistical Calculators
18. Sources
- ClinicalTrials.gov: SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Inhalation — NCT04631705.
- Registry record last updated 2024-10-03; status last verified 2024-06.
- Results first posted 2024-10-03.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
19. Record Summary
NCT04631705 is a randomized, triple-masked, sequential phase 1/2a trial of inhaled DZIF-10c in SARS-CoV-2-infected and uninfected individuals, sponsored by the University of Cologne. The registry lists enrollment of 45, a start date of 2020-12-14, primary completion on 2021-09-23, and status as terminated. Its primary outcome counts participants with any adverse event during the first 7 days after study drug administration.
Arm-level counts are posted, along with a safety summary reporting zero participants with serious adverse events and zero deaths in each group. The registry lists four secondary outcomes but does not report their numerical findings. It also lists no analyses, and does not report the reason for termination, detailed analysis populations, missing-data methods, or a comparative estimate for the primary outcome. The available record supports descriptive interpretation of the posted counts, with substantial limits on comparative and broader conclusions.